ABCC2 and neoplasm: While other mechanisms cannot be ruled out26,40–42, it is reasonable on the basis of the findings reported here to hypothesise that myricetin sensitises tumours to oxaliplatin antitumour activity by inhibiting oxaliplatin transport mediated by MRP2.